FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119648505> ?p ?o ?g. }

• W3119648505 abstract "The search for new antiepileptic drugs that would have greater margins of safety and fewer adverse effects is relevant. Thiazolidinone are a promising class for the development of new anticonvulsants. Aim. To conduct a screening study of new thiazolidinone derivatives for anticonvulsant activity on a seizure model induced by pentylenetetrazole and maximal electroshock; to analyze the structure – activity relationship; to reveal a lead-compound and investigate its dose-dependent manner. Materials and methods. Basic screening seizure models of pentylenetetrazol and maximal electroshock test were used in mice. The test original 9 thiazolidinone derivatives (100 mg/kg) and the reference drugs of sodium valproate (300 mg/kg), carbamazepine (40 mg/kg) were administered intragastrically 30 minutes before subcutaneous administration of pentylenetetrazol (90 mg/kg) or induction with maximal electroshock by giving a current with strength of 50 mA and frequency of 50 Hz for 0.2 s. In order to study the dose-dependent manner, the lead-compound was administered intragastrically in doses ranging from 25 mg/kg to 150 mg/kg. Results. A total of 9 compounds were studied, of which 3 did not affect experimental convulsions, 2 showed proconvulsive activity, and 4 had an anticonvulsant effect. The lead-compound 5-[( Z )-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone was determined under laboratory code Les-6222, which exhibited the highest anticonvulsant properties. The “structure–anticonvulsant activity” relationship in a series of thiazolidinone derivatives was analyzed. The dose-dependent manner of 5-[( Z )-(4-nitrobenzylidene)]-2-(thiazol-2-ylimino)-4-thiazolidinone anticonvulsant effect was studied using 2 seizure models, and the most effective dose of 100 mg / kg was identified. Conclusions. 5-[( Z )-(4-nitrobenzylidene)]-2-(thiazol-2-ylamino)-4-thiazolidinone is a promising compound for in-depth studies on anticonvulsant and related pharmacological activities in order to develop new original anticonvulsants." @default.
• W3119648505 created "2021-01-18" @default.
• W3119648505 creator A5012606660 @default.
• W3119648505 creator A5018379660 @default.
• W3119648505 creator A5033152311 @default.
• W3119648505 creator A5059298551 @default.
• W3119648505 creator A5076992453 @default.
• W3119648505 date "2020-12-09" @default.
• W3119648505 modified "2023-09-27" @default.
• W3119648505 title "Screening study of new thiazolidinone derivatives for anticonvulsant activity" @default.
• W3119648505 cites W1805190716 @default.
• W3119648505 cites W2487465067 @default.
• W3119648505 cites W2610279026 @default.
• W3119648505 cites W2765511902 @default.
• W3119648505 cites W2777270043 @default.
• W3119648505 cites W2786909024 @default.
• W3119648505 cites W2894133534 @default.
• W3119648505 cites W2905680424 @default.
• W3119648505 cites W2965424922 @default.
• W3119648505 cites W2982300731 @default.
• W3119648505 doi "https://doi.org/10.14739/2310-1210.2020.6.218463" @default.
• W3119648505 hasPublicationYear "2020" @default.
• W3119648505 type Work @default.
• W3119648505 sameAs 3119648505 @default.
• W3119648505 citedByCount "1" @default.
• W3119648505 countsByYear W31196485052022 @default.
• W3119648505 crossrefType "journal-article" @default.
• W3119648505 hasAuthorship W3119648505A5012606660 @default.
• W3119648505 hasAuthorship W3119648505A5018379660 @default.
• W3119648505 hasAuthorship W3119648505A5033152311 @default.
• W3119648505 hasAuthorship W3119648505A5059298551 @default.
• W3119648505 hasAuthorship W3119648505A5076992453 @default.
• W3119648505 hasBestOaLocation W31196485051 @default.
• W3119648505 hasConcept C118552586 @default.
• W3119648505 hasConcept C2775858608 @default.
• W3119648505 hasConcept C2778186239 @default.
• W3119648505 hasConcept C2910797910 @default.
• W3119648505 hasConcept C42219234 @default.
• W3119648505 hasConcept C71924100 @default.
• W3119648505 hasConcept C98274493 @default.
• W3119648505 hasConceptScore W3119648505C118552586 @default.
• W3119648505 hasConceptScore W3119648505C2775858608 @default.
• W3119648505 hasConceptScore W3119648505C2778186239 @default.
• W3119648505 hasConceptScore W3119648505C2910797910 @default.
• W3119648505 hasConceptScore W3119648505C42219234 @default.
• W3119648505 hasConceptScore W3119648505C71924100 @default.
• W3119648505 hasConceptScore W3119648505C98274493 @default.
• W3119648505 hasIssue "6" @default.
• W3119648505 hasLocation W31196485051 @default.
• W3119648505 hasLocation W31196485052 @default.
• W3119648505 hasOpenAccess W3119648505 @default.
• W3119648505 hasPrimaryLocation W31196485051 @default.
• W3119648505 hasRelatedWork W1876644323 @default.
• W3119648505 hasRelatedWork W1981032075 @default.
• W3119648505 hasRelatedWork W2067417329 @default.
• W3119648505 hasRelatedWork W2078940034 @default.
• W3119648505 hasRelatedWork W2120557693 @default.
• W3119648505 hasRelatedWork W2186970651 @default.
• W3119648505 hasRelatedWork W2395293583 @default.
• W3119648505 hasRelatedWork W2420509082 @default.
• W3119648505 hasRelatedWork W2460555486 @default.
• W3119648505 hasRelatedWork W3098210261 @default.
• W3119648505 hasVolume "0" @default.
• W3119648505 isParatext "false" @default.
• W3119648505 isRetracted "false" @default.
• W3119648505 magId "3119648505" @default.
• W3119648505 workType "article" @default.